The Efficacy and Safety of Esketamine for the Treatment-Resistant Depression in Older Adults: Comments on TRANSFORM-3 Trial Results

Affiliations

¹ Late Life Mood, Stress, and Wellness Program, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (HL), Los Angeles, CA. Electronic address: hlavrets@ucla.edu.
² College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute (SPR), New York, NY.

Editorial

Helen Lavretsky et al. Am J Geriatr Psychiatry. 2020 Feb.

. 2020 Feb;28(2):142-144.

doi: 10.1016/j.jagp.2019.10.009. Epub 2019 Oct 18.

¹ Late Life Mood, Stress, and Wellness Program, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (HL), Los Angeles, CA. Electronic address: hlavrets@ucla.edu.
² College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute (SPR), New York, NY.

No abstract available

Comment on

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, Singh JB. Ochs-Ross R, et al. Am J Geriatr Psychiatry. 2020 Feb;28(2):121-141. doi: 10.1016/j.jagp.2019.10.008. Epub 2019 Oct 17. Am J Geriatr Psychiatry. 2020. PMID: 31734084 Clinical Trial.